Earnings summaries and quarterly performance for EXACT SCIENCES.
Executive leadership at EXACT SCIENCES.
Kevin Conroy
Detailed
President and Chief Executive Officer
CEO
AB
Aaron Bloomer
Detailed
Executive Vice President and Chief Financial Officer
BB
Brian Baranick
Detailed
Executive Vice President and General Manager, Precision Oncology
JO
Jacob Orville
Detailed
Executive Vice President and General Manager, Screening
JH
James Herriott
Detailed
Senior Vice President, General Counsel
SC
Sarah Condella
Detailed
Executive Vice President, Human Resources & Service
Board of directors at EXACT SCIENCES.
DS
D. Scott Coward
Detailed
Director
DL
Daniel Levangie
Detailed
Director
JD
James Doyle
Detailed
Lead Independent Director
KZ
Katherine Zanotti
Detailed
Director
KP
Kimberly Popovits
Detailed
Director
LT
Leslie Trigg
Detailed
Director
MB
Michael Barber
Detailed
Director
PC
Paul Clancy
Detailed
Director
SP
Shacey Petrovic
Detailed
Director
Research analysts who have asked questions during EXACT SCIENCES earnings calls.
AB
Andrew Brackmann
William Blair & Company, L.L.C.
7 questions for EXAS
Also covers: ADPT, AWH, BDSX +11 more
Daniel Brennan
TD Cowen
7 questions for EXAS
Also covers: A, ADPT, AVTR +24 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
7 questions for EXAS
Also covers: A, ADPT, AVTR +21 more
Patrick Donnelly
Citi
7 questions for EXAS
Also covers: A, AVTR, BIO +21 more
PS
Puneet Souda
Leerink Partners
7 questions for EXAS
Also covers: A, ABCL, BRKR +20 more
SN
Subhalaxmi Nambi
Guggenheim Securities
7 questions for EXAS
Also covers: AKYA, BRKR, CSTL +15 more
Tycho Peterson
Jefferies
7 questions for EXAS
Also covers: A, AVTR, BIO +22 more
Vijay Kumar
Evercore ISI
7 questions for EXAS
Also covers: A, ABT, AVTR +21 more
Douglas Schenkel
Wolfe Research, LLC
6 questions for EXAS
Also covers: A, AVTR, BRKR +21 more
Jack Meehan
Nephron Research LLC
6 questions for EXAS
Also covers: A, AVTR, BIO +17 more
Andrew Cooper
Raymond James
5 questions for EXAS
Also covers: AZTA, CDNA, CTKB +12 more
DL
Daniel Leonard
Stifel Financial Corp.
4 questions for EXAS
Also covers: A, AVTR, BIO +15 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
3 questions for EXAS
Also covers: A, AVTR, CDXS +15 more
EB
Eve Burstein
Goldman Sachs
3 questions for EXAS
Also covers: GH, ILMN, PACB +1 more
Mark Massaro
BTIG, LLC
3 questions for EXAS
Also covers: ADPT, AKYA, BLLN +19 more
William Bonello
Craig-Hallum Capital Group
3 questions for EXAS
Also covers: BDSX, CDNA, CERS +6 more
CR
Catherine Ramsey
BTIG
2 questions for EXAS
Also covers: A, MTD, RVTY
Catherine Schulte
Baird
2 questions for EXAS
Also covers: A, CSTL, MRVI +7 more
KM
Kyle Mikson
Canaccord Genuity
2 questions for EXAS
Also covers: AKYA, BDSX, CSTL +12 more
Luke Sergott
Barclays
2 questions for EXAS
Also covers: A, AVTR, BRKR +19 more
SJ
Sung Ji Nam
Scotiabank
2 questions for EXAS
Also covers: ADPT, BDSX, BNGO +9 more
Brandon Couillard
Wells Fargo & Company
1 question for EXAS
Also covers: A, AVTR, BIO +10 more
Michael Ryskin
Bank of America Merrill Lynch
1 question for EXAS
Also covers: A, ALGN, AVTR +28 more
Recent press releases and 8-K filings for EXAS.
Exact Sciences Sale to Abbott Under Investigation by Halper Sadeh LLC
EXAS
Legal Proceedings
M&A
Takeover Bid
- Halper Sadeh LLC is investigating Exact Sciences Corporation (NASDAQ: EXAS) for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders.
- The investigation specifically concerns Exact Sciences' sale to Abbott for $105.00 per common share in cash.
- Shareholders are encouraged to contact the firm to discuss their legal rights and options, as the firm may seek increased consideration or additional disclosures.
7 days ago
Exact Sciences Reports Strong Prognostic Performance for Oncodetect Test
EXAS
New Projects/Investments
- Exact Sciences announced results from its Oncodetect molecular residual disease test, demonstrating strong prognostic performance in early triple-negative breast cancer.
- The NSABP B-59 substudy revealed that post-surgery MRD-positive status was associated with a 30-fold higher risk of distant recurrence compared to MRD-negative patients, while 95% of 147 analyzed patients who remained ctDNA-negative after surgery stayed free of distant recurrence at 3 years.
- The company plans to submit this data to MolDx in support of Medicare coverage and is collaborating with the NSABP Foundation on NSABP B-64, a prospective registry trial.
Dec 31, 2025, 12:25 PM
Exact Sciences Presents Oncodetect® MRD Test Results for Triple-Negative Breast Cancer
EXAS
New Projects/Investments
- Exact Sciences, in collaboration with the NSABP Foundation and the German Breast Group, presented positive clinical study results for its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS) on December 11, 2025.
- The Oncodetect test demonstrated strong prognostic performance, showing that post-surgical detection of circulating tumor DNA (ctDNA) was highly associated with the risk of distant recurrence in TNBC patients.
- Key findings include a ~30-fold higher risk of distant recurrence for patients who remained ctDNA-positive after surgery compared to ctDNA-negative patients, with 95% of MRD-negative patients remaining free of distant recurrence at 3 years.
- Exact Sciences plans to submit these data for publication in a peer-reviewed journal and to MolDx to support Medicare coverage for the Oncodetect test.
Dec 11, 2025, 10:30 PM
Exact Sciences Merger Investigation Announced
EXAS
M&A
Legal Proceedings
Takeover Bid
- Monteverde & Associates PC is investigating Exact Sciences Corporation (NASDAQ:EXAS) regarding its proposed sale to Abbott Laboratories.
- Under the terms of the transaction, Exact Sciences shareholders are expected to receive $105.00 per common share.
- The law firm is investigating whether this proposed deal is fair to shareholders.
Nov 28, 2025, 4:11 AM
Exact Sciences to be Acquired by Abbott Laboratories
EXAS
M&A
Takeover Bid
Revenue Acceleration/Inflection
- Abbott Laboratories announced a definitive agreement to acquire Exact Sciences Corporation on November 20, 2025.
- Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.
- The transaction, which includes Abbott absorbing Exact Sciences' estimated $1.8 billion of net debt, is expected to close in the second quarter of 2026.
- Exact Sciences is projected to generate more than $3 billion in revenue in 2025, and the acquisition is expected to be immediately accretive to Abbott's revenue growth and gross margin.
Nov 20, 2025, 1:02 PM
Exact Sciences Announces HSR Waiting Period Expiration and Updated 2025 Guidance
EXAS
Guidance Update
New Projects/Investments
- Exact Sciences announced the expiration of the Hart-Scott-Rodino (HSR) waiting period for its license agreement with Freenome.
- This agreement grants Exact Sciences exclusive rights in the United States to Freenome's blood-based colorectal cancer (CRC) screening tests, expanding Exact Science’s leadership in cancer screening.
- The exclusivity of the license remains subject to Freenome's test receiving first-line FDA approval.
- The company has updated its full year 2025 adjusted EBITDA guidance to reflect an initial $75 million cash payment for the licensing agreement, revising the range from $470 - $480 million to $395 - $405 million.
Nov 10, 2025, 12:00 PM
Exact Sciences Announces Positive Clinical Trial Results for Oncoguard Liver Test
EXAS
Product Launch
New Projects/Investments
- Exact Sciences announced breakthrough results from the ALTUS study for its Oncoguard® Liver blood test, demonstrating superior early detection of hepatocellular carcinoma (HCC).
- The Oncoguard® Liver blood test showed seven times greater sensitivity for very early-stage HCC compared to standard ultrasound surveillance.
- In the ALTUS study, the Oncoguard Liver test achieved 64% sensitivity for very early-stage HCC versus 9% for ultrasound, and 77% sensitivity for early-stage HCC versus 36% for ultrasound.
- The test also demonstrated a specificity of 82%.
- These findings will be presented at The Liver Meeting® on November 11, 2025.
Nov 7, 2025, 1:00 PM
Exact Sciences Announces Q3 2025 Results, Raises Full-Year Guidance, and Launches Cancerguard
EXAS
Earnings
Guidance Update
Product Launch
- Exact Sciences reported record total third quarter 2025 revenue of $851 million, marking a 20% increase on a reported and core revenue basis, with Screening revenue at $666 million and Precision Oncology revenue at $184 million.
- The company raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively, now projecting total revenue between $3.220 billion and $3.235 billion and adjusted EBITDA between $470 million and $480 million.
- For Q3 2025, Exact Sciences generated record cash from operations of $220 million and free cash flow of $190 million, representing increases of 59% and 69% respectively.
- The company's net loss for Q3 2025 was $20 million, or $0.10 per share, an improvement of $19 million and $0.10 per share compared to the same period in 2024.
- In September 2025, Exact Sciences launched Cancerguard®, its multi-cancer early detection test, for patients in the United States.
Nov 3, 2025, 9:07 PM
Exact Sciences Announces Third Quarter 2025 Results
EXAS
Earnings
Guidance Update
Product Launch
- Exact Sciences reported record total third quarter 2025 revenue of $851 million, marking a 20% increase on both a reported and core revenue basis compared to the same period in 2024.
- The company's net loss was $20 million, or $0.10 per share, an improvement of $19 million and $0.10 per share, respectively, while Adjusted EBITDA grew 37% to $135 million.
- Exact Sciences raised its full-year 2025 revenue guidance midpoint by $78 million to $3.220 - $3.235 billion and its adjusted EBITDA guidance midpoint by $10 million to $470 - $480 million.
- The company launched Cancerguard, its multi-cancer early detection test, for patients in the United States in September 2025.
- Exact Sciences generated record cash from operations of $220 million and free cash flow of $190 million, with cash, cash equivalents, and marketable securities totaling $1.00 billion at quarter-end.
Nov 3, 2025, 9:05 PM
Exact Sciences Presents New Cologuard Data at ACG 2025
EXAS
Product Launch
New Projects/Investments
- Exact Sciences presented new data at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2025, demonstrating how its Cologuard test improves adherence and closes colorectal cancer screening gaps.
- Research highlighted higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations.
- A study comparing next-generation mt-sDNA to FIT screening projected that mt-sDNA screened more than twice as many patients (713,000 vs 318,000) and detected 5.5x more advanced precancerous lesions and 3.7x more colorectal cancer cases, while reducing treatment costs by 3% and total costs by 2%.
- The Cologuard and FDA-approved Cologuard Plus tests are first-line, noninvasive colorectal cancer screening options for average-risk adults aged 45 or older, with Cologuard having been used over 20 million times since 2014.
Oct 27, 2025, 11:00 AM
Quarterly earnings call transcripts for EXACT SCIENCES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more